Patents by Inventor Wenyuan Qian

Wenyuan Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZO SEVEN-MEMBERED RING BIFUNCTIONAL COMPOUND AND APPLICATION THEREOF
    Publication number: 20240132482
    Abstract: The present invention relates to a benzo seven-membered ring bifunctional compound and an application thereof, and in particular to a compound represented by formula (IV) and a pharmaceutically acceptable salt thereof. The compound can be used for preparing a drug for treating diseases related to an estrogen receptor protein degradation targeting chimera.
    Type: Application
    Filed: January 29, 2022
    Publication date: April 25, 2024
    Applicants: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Zhengwei LI, Wenyuan QIAN, Shuhui CHEN
  • SALT FORM AND CRYSTAL FORM OF PYRAZOLE SUBSTITUTED IMIDAZO[1,2- A]QUINOXALINE DERIVATIVE
    Publication number: 20240132503
    Abstract: Provided are a salt form and a crystal form of a pyrazole substituted imidazo[1,2-a]quinoxaline derivative, and a preparation method therefor. Specifically disclosed are a salt form and a crystal form of a compound of formula (I), and a preparation method therefor and the use thereof in the preparation of drugs related to dual inhibitors of spleen tyrosine kinase (Syk) and vascular endothelial growth factor 2 (VEGFR2).
    Type: Application
    Filed: January 12, 2022
    Publication date: April 25, 2024
    Inventors: Wenyuan QIAN, Hongjian WANG, Liang TAN, Shuhui CHEN
  • [1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and use thereof
    Patent number: 11919896
    Abstract: Disclosed are a [1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and an application thereof in preparing a drug for treating a disease related to JAK1 or/and TYK2. Specifically, the present invention relates to a compound represented by formula (I), or an isomer or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: March 5, 2024
    Assignee: ZHUHAI UNITED LABORATORIES CO., LTD.
    Inventors: Weiwei Mao, Wenyuan Qian, Xuejian Zheng, Guoping Hu, Changqing Wei, Jian Li, Shuhui Chen
  • 1H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS AND APPLICATION THEREOF
    Publication number: 20230357241
    Abstract: A series of 1H-pyrrolo[2,3-c]pyridine compounds and an application thereof are provided. The compounds include those represented by formula (P) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 24, 2021
    Publication date: November 9, 2023
    Inventors: Wenyuan QIAN, Xiawei WEI, Chundao YANG, Guanghai XU, Ning JIANG, Shuhui CHEN
  • 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2
    Publication number: 20230219960
    Abstract: A class of spleen tyrosine kinase (Syk) and vascular endothelial growth factor 2 (VEGFR2) dual inhibitors, and specifically disclosed are a compound represented by formula (I), a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a Syk and VEGFR2 dual inhibitor related drug.
    Type: Application
    Filed: February 23, 2021
    Publication date: July 13, 2023
    Inventors: Wenyuan Qian, Hongjian Wang, Liang Tan, Shuhui Chen
  • DIMETHYLSULFOXIMINE DERIVATIVE
    Publication number: 20230219920
    Abstract: Disclosed in the present invention is a series of dimethylsulfoximine derivatives, and specifically disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 7, 2021
    Publication date: July 13, 2023
    Inventors: Wenyuan QIAN, Yonggang LIAO, Changqing WEI, Zhengying XI, Yao XIAO, Shuhui CHEN
  • BENZO FIVE-MEMBERED CYCLIC COMPOUND
    Publication number: 20230128137
    Abstract: A benzo five-membered cyclic compound represented by formula (I) or a pharmaceutically acceptable salt thereof has a significant effect in inhibiting the activity of anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: March 8, 2021
    Publication date: April 27, 2023
    Inventors: Hongjian WANG, Wenyuan QIAN, Ming ZHANG, Jian LI, Shuhui CHEN
  • Diazaindole derivative and use thereof as CHK1 inhibitor
    Patent number: 11634424
    Abstract: Disclosed are a diazaindole derivative as shown in formula I and the use thereof in the preparation of a drug for treating Chk1-related diseases.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: April 25, 2023
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Yonggang Liao, Wenyuan Qian, Changqing Wei, Yao Xiao, Zhengying Xi, Chen Zhang, Jian Li, Shuhui Chen
  • Macrocyclic compound serving as Wee1 inhibitor and applications thereof
    Patent number: 11613545
    Abstract: Disclosed in the present invention are a macrocyclic compound serving as a Weel inhibitor, and applications thereof in the preparation of drugs for treating Weel-related diseases. The present invention specifically relates to a compound represented by formula (II), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: March 28, 2023
    Assignee: WUXI BIOCITY BIOPHARMACEUTICS CO., LTD.
    Inventors: Wenyuan Qian, Chundao Yang, Zhengwei Li, Jie Li, Jian Li, Shuhui Chen
  • CRYSTALLINE FORM OF JAK INHIBITOR AND APPLICATION THEREOF
    Publication number: 20230091250
    Abstract: The present invention discloses the crystal forms as a JAK inhibitor and their application in the preparation of drugs for the treatment of JAK1 or/and TYK2 related diseases.
    Type: Application
    Filed: February 22, 2021
    Publication date: March 23, 2023
    Inventors: Weiwei MAO, Wenyuan QIAN, Changqing WEI, Liang FANG, Liwei MU, Shuhui CHEN
  • SALT FORM AND CRYSTAL FORM OF MUTANT IDH1 INHIBITOR AND PREPARATION METHOD THEREFOR
    Publication number: 20230045991
    Abstract: A salt form and crystal form of a mutant IDHI inhibitor and a preparation method therefor.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 16, 2023
    Applicant: KPC PHARMACEUTICALS, INC.
    Inventors: Yaxian CAI, Bao YUE, Peng YU, Changqing WEI, Wenyuan QIAN
  • TRI-HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND USE THEREOF
    Publication number: 20230017539
    Abstract: Disclosed are a tri-heterocyclic compound as a JAK inhibitor, and the use thereof in the preparation of a drug for treating JAK1- or/and JAK2-related diseases. Specifically, the present invention relates to a compound as shown in formula (I?) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 27, 2020
    Publication date: January 19, 2023
    Inventors: Weiwei MAO, Wenlong LI, Changqing WEI, Wenyuan QIAN, Guoping HU, Jian LI, Shuhui CHEN
  • DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR
    Publication number: 20230017858
    Abstract: Disclosed are a diazaindole derivative as shown in formula I and the use thereof in the preparation of a drug for treating Chk1-related diseases.
    Type: Application
    Filed: November 27, 2020
    Publication date: January 19, 2023
    Inventors: Yonggang LIAO, Wenyuan QIAN, Changqing WEI, Yao XIAO, Zhengying XI, Chen ZHANG, Jian LI, Shuhui CHEN
  • CRYSTALLINE FORM OF ATR INHIBITOR AND USE THEREOF
    Publication number: 20220281858
    Abstract: Disclosed are a crystalline form of an ATR inhibitor, a preparation method therefore, and the use thereof in the preparation of a drug for treating ATR-related diseases.
    Type: Application
    Filed: August 6, 2020
    Publication date: September 8, 2022
    Inventors: Jian WANG, Ting YAO, Wenyuan QIAN, Jian LI, Shuhui CHEN
  • ATR inhibitor and application thereof
    Patent number: 11434232
    Abstract: Disclosed are a compound as an ATR inhibitor and an application in preparing a drug as an ATR inhibitor. In particular, disclosed is a compound represented by formula (I) or an isomer or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 2, 2019
    Date of Patent: September 6, 2022
    Assignee: Wuxi Biocity Biopharmaceutics Co., Ltd.
    Inventors: Wenyuan Qian, Jian Wang, Jie Li, Jian Li, Shuhui Chen
  • Benzimidazole derivatives and use thereof as IDH1 inhibitors
    Patent number: 11407717
    Abstract: The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: August 9, 2022
    Assignee: KPC PHARMACEUTICALS, INC.
    Inventors: Dahai Wang, Wenyuan Qian, Shilan Liu, Shuhui Chen
  • PYRROLOPYRIMIDINE COMPOUND AND USE THEREOF
    Publication number: 20220227788
    Abstract: The present invention relates to a pyrrolopyrimidine compound used as a JAK inhibitor, and the use thereof in the preparation of a drug for treating a JAK1- and/or JAK2-associated disease, and in specifically relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 5, 2020
    Publication date: July 21, 2022
    Inventors: Wenyuan QIAN, Changqing WEI, Guoping HU, Jian LI, Shuhui CHEN
  • CRYSTAL FORM OF WEE1 INHIBITOR COMPOUND AND USE THEREOF
    Publication number: 20220220120
    Abstract: Disclosed is a crystal form of a compound of formula (I) and the use of the crystal form in the preparation of a drug for treating Wee1-related diseases.
    Type: Application
    Filed: April 30, 2020
    Publication date: July 14, 2022
    Inventors: Wenyuan QIAN, Chundao YANG, Zhengwei LI, Jie LI, Jian LI, Shuhui CHEN
  • Heterocyclic compound as CSF-1R inhibitor and use thereof
    Patent number: 11384065
    Abstract: The present invention relates to a class of isoindolinone derivatives and use thereof in the preparation of a medicament for treating diseases associated with a novel colony stimulating factor 1 receptor (CSF-1R) inhibitor. In particular, the present invention relates to a compound of formula (I) and a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: July 12, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Wenyuan Qian, Chundao Yang, Guanghai Xu, Jie Li, Jian Li, Shuhui Chen
  • Polymorph of HDAC6-selective inhibitor and application thereof
    Patent number: 11345682
    Abstract: Disclosed in the present invention are a polymorph A of a compound represented by formula (I), and an application thereof in preparation of drugs for treating HDAC6-associated diseases.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: May 31, 2022
    Assignees: CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD., CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD., CSTONE PHARMACEUTICALS
    Inventors: Qiang Guo, Changqing Wei, Yao Xiao, Lili Fan, Wenyuan Qian